Cencora Inc. (COR), a bio-tech company in the specialty drugs market, seems to be on a positive trajectory according to market experts. Well-known financial analyst Jim Cramer recommends doubling down on the firm. Index fund FERGUSON WELLMAN CAPITAL MANAGEMENT, INC added a significant 79,430 shares of Cencora to their portfolio. Despite a drop in trading volume, the firm has managed to constantly beat earnings estimates. It further raised its annual profit forecast citing strong demand for specialty drugs. Cencora has also enhanced its receivables purchase agreement for improved liquidity. The firm has gained a fresh momentum as it entered into a €1 billion senior notes agreement. Wells Fargo has twice upgraded its rating, lifting the price target from $275 to $300 and then to $337. However, there are concerns about Cencora's debt, and insider exits. Construing the positive indicators, many experts recommend addition of Cencora's stocks to portfolios. To top it all, the fiscal Q2 2025 earnings beat expectations, leading to a surge in the stock value. However, there are concerns about the firm's reduced trading volume ranking amid cybersecurity issues.<
Cencora COR News Analytics from Thu, 01 Aug 2024 07:00:00 GMT to Sat, 12 Jul 2025 18:40:11 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor 6
